Stanley Watowich
Company: Ridgeline Therapeutics
Job title: Founder & Chief Executive Officer
Seminars:
3.15 pm Panel Discussion: Designing Therapies with Novel Mechanisms & Predictive Biomarkers to Holistically Improve Treatment for Better Patient Outcomes 3:15 pm
Integrating the design of therapies involving novel mechanisms with new, predictive biomarkers to provide a more precise and efficient approach to drug discovery and development for earlier identification of responders and non-responders Leveraging cutting-edge understanding of MASH pathogenesis to design innovative therapies to target the root causes of the disease for more effective treatments that…Read more
day: Combination & Sequential Therapy Focus Day
9:15 am Sustainable Treatments to Reverse MASH & Obesity-Linked Comorbidities 9:15 am
Quelling hepatic injury through strategic inflammatory modulation to dampen the damaging inflammatory cascade within the liver to benefit the long-term trajectory of the disease Understanding the biology of targeting chemokine receptors (e.g., CCR2/CCR5 inhibition) to limit the recruitment of inflammatory cells to the liver to introduce a new method of treating MASH Investigating the potential…Read more
day: Combination & Sequential Therapy Focus Day